Immunovant, Inc.
IMVT
$31.53
-$0.08-0.25%
NASDAQ
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 11.85% | -11.85% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 39.52% | -13.21% | |||
| Operating Income | -39.52% | 13.21% | |||
| Income Before Tax | -38.15% | 13.36% | |||
| Income Tax Expenses | -283.25% | 161.28% | |||
| Earnings from Continuing Operations | -33.64% | 12.54% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -33.64% | 12.54% | |||
| EBIT | -39.52% | 13.21% | |||
| EBITDA | -39.56% | 13.21% | |||
| EPS Basic | -19.08% | 16.33% | |||
| Normalized Basic EPS | -23.11% | 17.12% | |||
| EPS Diluted | -19.08% | 16.33% | |||
| Normalized Diluted EPS | -23.11% | 17.12% | |||
| Average Basic Shares Outstanding | 12.23% | 4.53% | |||
| Average Diluted Shares Outstanding | 12.23% | 4.53% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||